000276155 001__ 276155
000276155 005__ 20250204165927.0
000276155 0247_ $$2doi$$a10.1007/s00259-024-06944-y
000276155 0247_ $$2pmid$$apmid:39404789
000276155 0247_ $$2ISSN$$a1619-7070
000276155 0247_ $$2ISSN$$a1619-7089
000276155 037__ $$aDZNE-2025-00227
000276155 041__ $$aEnglish
000276155 082__ $$a610
000276155 1001_ $$aKunte, Sophie C$$b0
000276155 245__ $$aPET/CT imaging of differentiated and medullary thyroid carcinoma using the novel SSTR-targeting peptide [18F]SiTATE - first clinical experiences.
000276155 260__ $$aHeidelberg [u.a.]$$bSpringer-Verl.$$c2025
000276155 3367_ $$2DRIVER$$aarticle
000276155 3367_ $$2DataCite$$aOutput Types/Journal article
000276155 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1738669147_28058
000276155 3367_ $$2BibTeX$$aARTICLE
000276155 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000276155 3367_ $$00$$2EndNote$$aJournal Article
000276155 520__ $$aThe novel 18F-labeled somatostatin receptor (SSTR)-directed radiotracer [18F]SiTATE demonstrated promising results for the imaging of various SSTR-expressing tumor types. Although thyroid carcinomas (TC) express SSTR, data on [18F]SiTATE PET/CT imaging in TC are lacking. This study explores the use of [18F]SiTATE PET/CT in a patient cohort with histologically proven TC.As part of a prospective observational study at a single tertiary cancer center, 21 patients with TC (10 medullary (MTC) and 11 differentiated (DTC)) who underwent at least one [18F]SiTATE PET/CT were included (37 scans in total). Mean SUVmax and SUVmean of tumoral lesions, mean total-tumor-volume (TTV), and whole-body (WB)-SUVmax and WB-SUVmean on PET with their standard deviations (SDs) were determined. PET parameters were correlated to clinical parameters including tumor marker levels (thyroglobulin for DTC, calcitonin for MTC).89 lesions were included in the analysis. Metastases were localized in the bone, lymph nodes, lung, soft tissue, and thyroid bed. Osseous (31 lesions; SUVmax 8.6 ± 8.0; SUVmean 5.8 ± 5.4) and nodal (37 lesions; SUVmax 8.7 ± 7.8; SUVmean 5.7 ± 5.4) metastases showed the highest uptake. The MTC disease burden on PET significantly correlated with the calcitonin tumor marker level (e.g., TTV: r = 0.771, r2 = 0.594, p = 0.002). For DTC, no such correlation was present.Our data demonstrate high feasibility of [18F]SiTATE PET/CT in a small cohort of patients with MTC and DTC. The use of [18F]SiTATE may overcome logistical disadvantages of 68Ga-based tracers and facilitate SSTR-targeted PET/CT imaging of thyroid carcinoma.
000276155 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x0
000276155 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000276155 650_7 $$2Other$$a(4–6): Medullary thyroid carcinoma (MTC)
000276155 650_7 $$2Other$$aDifferentiated thyroid carcinoma (DTC)
000276155 650_7 $$2Other$$aFollicular thyroid carcinoma (FTC)
000276155 650_7 $$2Other$$aPapillary thyroid carcinoma (PTC)
000276155 650_7 $$2Other$$aSerum tumor marker
000276155 650_7 $$2Other$$aSomatostatin receptor (SSTR)
000276155 650_7 $$2NLM Chemicals$$aReceptors, Somatostatin
000276155 650_7 $$2NLM Chemicals$$aFluorine Radioisotopes
000276155 650_2 $$2MeSH$$aHumans
000276155 650_2 $$2MeSH$$aThyroid Neoplasms: diagnostic imaging
000276155 650_2 $$2MeSH$$aThyroid Neoplasms: metabolism
000276155 650_2 $$2MeSH$$aMale
000276155 650_2 $$2MeSH$$aFemale
000276155 650_2 $$2MeSH$$aPositron Emission Tomography Computed Tomography
000276155 650_2 $$2MeSH$$aMiddle Aged
000276155 650_2 $$2MeSH$$aCarcinoma, Neuroendocrine: diagnostic imaging
000276155 650_2 $$2MeSH$$aReceptors, Somatostatin: metabolism
000276155 650_2 $$2MeSH$$aAdult
000276155 650_2 $$2MeSH$$aAged
000276155 650_2 $$2MeSH$$aFluorine Radioisotopes
000276155 7001_ $$aWenter, Vera$$b1
000276155 7001_ $$aToms, Johannes$$b2
000276155 7001_ $$aLindner, Simon$$b3
000276155 7001_ $$aUnterrainer, Marcus$$b4
000276155 7001_ $$aEilsberger, Friederike$$b5
000276155 7001_ $$aJurkschat, Klaus$$b6
000276155 7001_ $$aWängler, Carmen$$b7
000276155 7001_ $$aWängler, Björn$$b8
000276155 7001_ $$aSchirrmacher, Ralf$$b9
000276155 7001_ $$aTiling, Maximilian W$$b10
000276155 7001_ $$aSheikh, Gabriel T$$b11
000276155 7001_ $$aMehrens, Dirk$$b12
000276155 7001_ $$0P:(DE-2719)9001539$$aBrendel, Matthias$$b13$$udzne
000276155 7001_ $$aRübenthaler, Johannes$$b14
000276155 7001_ $$aAuernhammer, Christoph J$$b15
000276155 7001_ $$aSpitzweg, Christine$$b16
000276155 7001_ $$aUnterrainer, Lena M$$b17
000276155 7001_ $$00000-0002-9566-8438$$aHolzgreve, Adrien$$b18
000276155 773__ $$0PERI:(DE-600)2098375-X$$a10.1007/s00259-024-06944-y$$gVol. 52, no. 3, p. 900 - 912$$n3$$p900 - 912$$tEuropean journal of nuclear medicine and molecular imaging$$v52$$x1619-7070$$y2025
000276155 8564_ $$uhttps://pub.dzne.de/record/276155/files/DZNE-2025-00227.pdf$$yOpenAccess
000276155 8564_ $$uhttps://pub.dzne.de/record/276155/files/DZNE-2025-00227.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000276155 909CO $$ooai:pub.dzne.de:276155$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000276155 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001539$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b13$$kDZNE
000276155 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x0
000276155 9141_ $$y2025
000276155 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-05
000276155 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-05
000276155 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-05
000276155 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000276155 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-05
000276155 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J NUCL MED MOL I : 2022$$d2024-12-05
000276155 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-05
000276155 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2024-12-05$$wger
000276155 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-05
000276155 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000276155 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-05
000276155 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR J NUCL MED MOL I : 2022$$d2024-12-05
000276155 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-05
000276155 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-05
000276155 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-05
000276155 9201_ $$0I:(DE-2719)1110007$$kAG Haass$$lMolecular Neurodegeneration$$x0
000276155 980__ $$ajournal
000276155 980__ $$aVDB
000276155 980__ $$aUNRESTRICTED
000276155 980__ $$aI:(DE-2719)1110007
000276155 9801_ $$aFullTexts